Skip to Main Content

Paper Details

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Blood Cancer Discov
28
2023
Author NameAffiliation
Curtis A LachowiezThe University of Texas MD Anderson Cancer Center
Marlise R LuskinDana-Farber Cancer Institute
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2